{"id":68513,"date":"2026-06-18T22:51:37","date_gmt":"2026-06-18T14:51:37","guid":{"rendered":"https:\/\/flcube.com\/?p=68513"},"modified":"2026-06-18T22:51:38","modified_gmt":"2026-06-18T14:51:38","slug":"alebund-pharmaceuticals-raises-163m-in-hong-kong-ipo-to-advance-kidney-disease-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68513","title":{"rendered":"Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Alebund Pharmaceuticals (Jiangsu) Limited<\/strong> (HKG: 9637) successfully completed its <strong>initial public offering (IPO)<\/strong> on the <strong>Hong Kong Stock Exchange<\/strong>, raising <strong>HKD 1.28 billion (USD 163 million)<\/strong> through the sale of <strong>56,755,400 shares<\/strong> at <strong>HKD 22.6 (USD 2.88)<\/strong> per share. The China-based biopharmaceutical company, founded in 2018, focuses exclusively on developing innovative therapies for chronic kidney disease (CKD) and related complications.<\/p>\n\n\n\n<h2 id=\"h-transaction-details\" class=\"wp-block-heading\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Alebund Pharmaceuticals (Jiangsu) Limited<\/td><\/tr><tr><td><strong>Stock Code<\/strong><\/td><td>HKG: 9637<\/td><\/tr><tr><td><strong>IPO Proceeds<\/strong><\/td><td>HKD 1.28 billion (USD 163 million)<\/td><\/tr><tr><td><strong>Shares Offered<\/strong><\/td><td>56,755,400<\/td><\/tr><tr><td><strong>Price per Share<\/strong><\/td><td>HKD 22.6 (USD 2.88)<\/td><\/tr><tr><td><strong>Listing Date<\/strong><\/td><td>June 2026<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Clinical development, regulatory submissions, and commercial preparation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-pipeline-overview-seven-product-portfolio\" class=\"wp-block-heading\">Pipeline Overview \u2013 Seven-Product Portfolio<\/h2>\n\n\n\n<h3 id=\"h-core-product-ap301-late-stage\" class=\"wp-block-heading\">Core Product \u2013 AP301 (Late-Stage)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication:<\/strong> Hyperphosphatemia in dialysis patients with CKD<\/li>\n\n\n\n<li><strong>Status:<\/strong> Completed Phase III registration trial in China; NDA submission expected imminently<\/li>\n\n\n\n<li><strong>Global Development:<\/strong> Ongoing multinational Phase III pivotal trial (MRCT) in US and China<\/li>\n\n\n\n<li><strong>Market Need:<\/strong> Addresses one of the most common and serious complications of CKD in dialysis patients<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-lead-clinical-candidate-ap306-late-stage\" class=\"wp-block-heading\">Lead Clinical Candidate \u2013 AP306 (Late-Stage)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Differentiated pan-phosphate transporter inhibitor<\/li>\n\n\n\n<li><strong>Partnership:<\/strong> Licensed from Japan&#8217;s Chugai Pharmaceutical<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> Granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> by China&#8217;s NMPA<\/li>\n\n\n\n<li><strong>Target Population:<\/strong> Hyperphosphatemia in dialysis patients with CKD<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-preclinical-candidates\" class=\"wp-block-heading\">Preclinical Candidates<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Indication<\/th><th>Key Differentiation<\/th><th>Regulatory Status<\/th><\/tr><\/thead><tbody><tr><td><strong>AP303<\/strong><\/td><td>ADPKD, IgAN, DKD, FSGS<\/td><td>Disease-modifying approach to halt\/slow CKD progression<\/td><td>FDA Orphan Drug Designation for ADPKD<\/td><\/tr><tr><td><strong>AP308<\/strong><\/td><td>IgA nephropathy (IgAN)<\/td><td>Recombinant IgA protease for functional cure<\/td><td>Technology licensed from Peking University First Hospital<\/td><\/tr><tr><td><strong>AP304, AP305, AP307<\/strong><\/td><td>Various CKD subtypes<\/td><td>Early-stage differentiated candidates<\/td><td>Preclinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-opportunity\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CKD Market Size:<\/strong> Affects over 850 million people globally with limited disease-modifying treatment options<\/li>\n\n\n\n<li><strong>Hyperphosphatemia Burden:<\/strong> Impacts approximately 70% of dialysis patients, requiring daily phosphate binder therapy<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> AP301 and AP306 offer differentiated mechanisms compared to existing phosphate binders<\/li>\n\n\n\n<li><strong>Regulatory Catalysts:<\/strong> Multiple near-term opportunities including AP301 NDA submission and AP306 BTD benefits<\/li>\n\n\n\n<li><strong>Technology Platform:<\/strong> Proprietary approaches spanning small molecules, biologics, and enzyme replacement strategies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The IPO provides Alebund with substantial capital to advance its lead assets through late-stage development and prepare for commercial launch, while maintaining a robust early-stage pipeline addressing diverse aspects of kidney disease pathology.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-differentiation\" class=\"wp-block-heading\">Competitive Landscape &amp; Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AP301:<\/strong> Potential first-in-class phosphate binder with improved tolerability profile compared to current standard of care<\/li>\n\n\n\n<li><strong>AP306:<\/strong> Only pan-phosphate transporter inhibitor in development with BTD status, potentially offering superior efficacy<\/li>\n\n\n\n<li><strong>AP303:<\/strong> One of few disease-modifying approaches targeting multiple forms of progressive CKD<\/li>\n\n\n\n<li><strong>AP308:<\/strong> Novel functional cure strategy for IgAN, a condition with no approved disease-modifying therapies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory submissions, market opportunities, and use of IPO proceeds. Actual results may differ materially due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061800026_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061800026_c.\"><\/object><a id=\"wp-block-file--media-b01b92e0-bc7b-4f27-8f2a-e1dadf3e3dec\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061800026_c.pdf\">2026061800026_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061800026_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b01b92e0-bc7b-4f27-8f2a-e1dadf3e3dec\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) successfully completed its initial public offering (IPO) on the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68515,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[627,4811,72],"class_list":["post-68513","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-alebund-pharmaceuticals","tag-hkg-9637","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, raising HKD 1.28 billion (USD 163 million) through the sale of 56,755,400 shares at HKD 22.6 (USD 2.88) per share. The China-based biopharmaceutical company, founded in 2018, focuses exclusively on developing innovative therapies for chronic kidney disease (CKD) and related complications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68513\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline\" \/>\n<meta property=\"og:description\" content=\"Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, raising HKD 1.28 billion (USD 163 million) through the sale of 56,755,400 shares at HKD 22.6 (USD 2.88) per share. The China-based biopharmaceutical company, founded in 2018, focuses exclusively on developing innovative therapies for chronic kidney disease (CKD) and related complications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68513\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-18T14:51:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-18T14:51:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1801.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68513#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68513\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline\",\"datePublished\":\"2026-06-18T14:51:37+00:00\",\"dateModified\":\"2026-06-18T14:51:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68513\"},\"wordCount\":455,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68513#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1801.webp\",\"keywords\":[\"Alebund Pharmaceuticals\",\"HKG: 9637\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68513#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68513\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68513\",\"name\":\"Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68513#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68513#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1801.webp\",\"datePublished\":\"2026-06-18T14:51:37+00:00\",\"dateModified\":\"2026-06-18T14:51:38+00:00\",\"description\":\"Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, raising HKD 1.28 billion (USD 163 million) through the sale of 56,755,400 shares at HKD 22.6 (USD 2.88) per share. The China-based biopharmaceutical company, founded in 2018, focuses exclusively on developing innovative therapies for chronic kidney disease (CKD) and related complications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68513#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68513\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68513#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1801.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1801.webp\",\"width\":1080,\"height\":608,\"caption\":\"Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68513#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, raising HKD 1.28 billion (USD 163 million) through the sale of 56,755,400 shares at HKD 22.6 (USD 2.88) per share. The China-based biopharmaceutical company, founded in 2018, focuses exclusively on developing innovative therapies for chronic kidney disease (CKD) and related complications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68513","og_locale":"en_US","og_type":"article","og_title":"Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline","og_description":"Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, raising HKD 1.28 billion (USD 163 million) through the sale of 56,755,400 shares at HKD 22.6 (USD 2.88) per share. The China-based biopharmaceutical company, founded in 2018, focuses exclusively on developing innovative therapies for chronic kidney disease (CKD) and related complications.","og_url":"https:\/\/flcube.com\/?p=68513","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-18T14:51:37+00:00","article_modified_time":"2026-06-18T14:51:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1801.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68513#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68513"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline","datePublished":"2026-06-18T14:51:37+00:00","dateModified":"2026-06-18T14:51:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68513"},"wordCount":455,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68513#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1801.webp","keywords":["Alebund Pharmaceuticals","HKG: 9637","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68513#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68513","url":"https:\/\/flcube.com\/?p=68513","name":"Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68513#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68513#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1801.webp","datePublished":"2026-06-18T14:51:37+00:00","dateModified":"2026-06-18T14:51:38+00:00","description":"Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange, raising HKD 1.28 billion (USD 163 million) through the sale of 56,755,400 shares at HKD 22.6 (USD 2.88) per share. The China-based biopharmaceutical company, founded in 2018, focuses exclusively on developing innovative therapies for chronic kidney disease (CKD) and related complications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68513#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68513"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68513#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1801.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1801.webp","width":1080,"height":608,"caption":"Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68513#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1801.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68513"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68513\/revisions"}],"predecessor-version":[{"id":68516,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68513\/revisions\/68516"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68515"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}